phase 2 study of the combination therapy, docetaxel and trastuzumab, for advanced extramammary Paget's disease.
Not Applicable
- Conditions
- extramammary Paget's disease
- Registration Number
- JPRN-UMIN000021311
- Lead Sponsor
- Keio University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 13
Inclusion Criteria
Not provided
Exclusion Criteria
1) Have a history of hypersensitivity to components of the chemotherapeutic drugs 2) Women who may possibly be pregnant or pregnant 3) Patients with severe cardiac dysfunction 4) Has known active central nervous system (CNS) metastasis. 5) Has uncontrolled disease that might confound the results of the study, or is not best interest of the subject to participate, in the opinion of the treating investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method